Veraxa Biotech AGNASDAQ: VRXA

VERAXA Biotech (NASDAQ: VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program

· Issued by Veraxa Biotech AG

Summary by 6ix AI

VERAXA Biotech, a developer of antibody-based therapeutics, began cell line development for its lead BiTAC T-cell engager program through a collaboration with ATUM. ATUM will use its Leap-In Transposase technology to make stable clonal cell lines supporting IND/CTA-enabling work (steps toward applications to start clinical trials) and future clinical development.

Key details

  • The collaboration is intended to support CMC (chemistry, manufacturing and controls) development, including early process, analytical and formulation development, and production of material for nonclinical studies.
  • The collaboration follows preclinical data presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting.
  • VERAXA says its BiTAC T-cell engager platform is designed to improve tumor selectivity by splitting the T-cell engager into two complementary precursors that activate only when both bind separate tumor targets on the same cell.
  • The company believes this approach could reduce off-tumor toxicity linked to conventional T-cell engagers while keeping anti-cancer activity, potentially allowing higher dosing and a broader therapeutic window.

6ix AI wrote this summary from the release below and checked it against the release.

Featured Image

Austin, Texas, United States, July 2nd, 2026, FinanceWire

VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager ("BiTAC-TCE") program through a collaboration with ATUM, which will apply its Leap-In Transposase(R) technology to generate stable clonal cell lines supporting IND/CTA-enabling activities and future clinical development. The collaboration follows encouraging preclinical data presented at the 2026 American Association for Cancer Research ("AACR") Annual Meeting and is intended to support CMC development, including early process, analytical and formulation development, as well as the production of material for nonclinical studies.

VERAXA said its BiTAC-TCE platform is designed to improve tumor selectivity by splitting the T-cell engager into two complementary precursors that activate only when both bind separate tumor targets on the same cell. The company believes this conditional "AND"-gated approach could reduce off-tumor toxicity associated with conventional T-cell engagers while maintaining anti-cancer activity, potentially enabling higher dosing and a broader therapeutic window.

To view the full press release, visit https://ibn.fm/FCIlk

About VERAXA Biotech AG

At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.

BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to VRXA are available in the company's newsroom at https://ibn.fm/VRXA

Contact
IBNwww.InvestorBrandNetwork.comEditor@InvestorBrandNetwork.com

Veraxa Biotech AG on 6ix

Earlier from Veraxa Biotech

Later from Veraxa Biotech

All Veraxa Biotech news releases